Skip to content

Base editing corrects alpha-1 antitrypsin gene defect in a patient's liver, case report shows

A one-off infusion of an experimental base-editing therapy corrected more than half of the faulty gene copies in a 66-year-old man's liver. The peer-reviewed evidence so far is that single case.

Science

By Comlumen Desk Compiled stories

3 min read

Compiled by the Comlumen Desk from the reporting and official sources listed at the end of this story, and written with AI assistance. It contains no original reporting by Comlumen. How we report

Illustration of a DNA double helix
An illustration of the DNA double helix. National Human Genome Research Institute / Wikimedia Commons, public domain

In this story
  1. The condition
  2. The treatment
  3. What the paper shows
  4. The wider picture
  5. Caveats
  6. In their words
  7. How this story was sourced

Doctors at Hannover Medical School (MHH) in Germany and Ren Ji Hospital in Shanghai have reported that an experimental gene-editing treatment corrected the genetic error behind alpha-1 antitrypsin deficiency in a patient's liver. The peer-reviewed evidence is a single-patient case report in the Journal of Hepatology, published online on 2 November 2026.

How this story was sourced.

6 sources from 6 organisations, all of them official or primary documents.

Official and primary documents 6

The body that made the decision, the paper, or the organisation’s own release.

  1. Journal of Hepatology Liver biopsy confirms precise and efficient correction of SERPINA1 after in vivo base editing in a patient with alpha-1 antitrypsin deficiency journal-of-hepatology.eu
  2. PubMed abstract of the Journal of Hepatology case report pubmed.ncbi.nlm.nih.gov
  3. Elsevier via EurekAlert Gene correction therapy successfully treats alpha-1 antitrypsin deficiency in vivo eurekalert.org
  4. Hannover Medical School via idw press release on base editing for alpha-1 antitrypsin deficiency idw-online.de
  5. YolTech proof-of-concept data for YOLT-202 at the European Respiratory Society Congress 2026 yoltx.com
  6. ClinicalTrials.gov Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (NCT07193615) clinicaltrials.gov
The sources as the story lists them

Sources

Comlumen Desk Compiled stories
Stories under the Comlumen Desk byline are compiled from reporting by other news organisations and from official sources, and written with AI assistance. They contain no original reporting by Comlumen. Every source is listed and linked at the end of each story, and facts are attributed in the text to the organisation that reported them. How we report.

The story so far. More on Gene editing, Health and Rare disease.

  1. Technology Hackers tamper with fridges storing France's blood plasma; alarms prevent losses Attackers raised temperature settings at three cold-storage sites of France's national blood service overnight on 1 to 2 November 2026, through a refrigeration contractor. The service says no blood products were lost.
  2. Science More US newborns are missing the vitamin K shot, and bleeding risk is higher, study finds A JAMA study of more than 5.2 million US births found the share of newborns not given vitamin K more than doubled between 2017 and 2025, and those infants had higher rates of bleeding, including bleeding in the brain.
  3. Science Lancet Countdown calls climate change a health emergency as heat deaths hit record The 2026 Lancet Countdown report estimates that heat was linked to about 710,000 deaths in 2023 and, for the first time, attributes more than 70% of that toll to human-caused warming.
More Science
Made byStacklumen